Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to -$1.8 million.

  • Lineage Cell Therapeutics' Net Cash Flow rose 567.82% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.4 million, marking a year-over-year increase of 42235.48%. This contributed to the annual value of $10.5 million for FY2024, which is 5697.77% down from last year.
  • Lineage Cell Therapeutics' Net Cash Flow amounted to -$1.8 million in Q3 2025, which was up 567.82% from -$5.9 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Net Cash Flow high stood at $23.6 million for Q1 2021, and its period low was -$45.4 million during Q3 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' median Net Cash Flow value was -$1.2 million (recorded in 2021), while the average stood at $464000.0.
  • Data for Lineage Cell Therapeutics' Net Cash Flow shows a peak YoY increase of 1063318.18% (in 2021) and a maximum YoY decrease of 685333.33% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' Net Cash Flow stood at -$5.1 million in 2021, then tumbled by 162.25% to -$13.3 million in 2022, then surged by 127.93% to $3.7 million in 2023, then soared by 385.8% to $18.0 million in 2024, then plummeted by 109.95% to -$1.8 million in 2025.
  • Its Net Cash Flow was -$1.8 million in Q3 2025, compared to -$5.9 million in Q2 2025 and $2.1 million in Q1 2025.